The most well-characterized CD74 inhibitor is Milatuzumab, a monoclonal antibody approved for the treatment of chronic lymphocytic leukemia with acceptable side effects in humans including leukopenia, rash, nausea, and vomiting at low grade (65). Here, CD74 is linked to B-cell chronic lymphocytic leukemia.